Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Anticipated CAGR of the GLP 1 Receptor Agonist Market, and What Factors Will Drive It?

In recent times, the market size for GLP-1 receptor agonist has seen a steady increase. It is projected to expand from $13.58 billion in 2024 to $14.22 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 4.7%. The growth observed in the past can be credited to various factors such as an increase in diabetes cases, clinical efficiency, increased awareness and acceptance by patients, international health campaigns, and a preference for injectable treatments by patients.

Expectations are high for notable expansion in the GLP-1 receptor agonist market in the coming years. It is predicted that the market will reach $17.72 billion by 2029, following a compound annual growth rate of 5.7%. Several factors contribute to this projected boost during the forecast period such as increased priority on lifestyle management, the advancement of personalised medicine, broadening indications, the emergence of next-generation commodities, and the implementation of combination therapies. Key trends to watch during this period are the launch of oral formulations, a prioritisation of combination therapies, strategic partnerships and collaborations, adaptation of reimbursement policies and accessibility, and patient-focused approaches.

Which Major Market Drivers Are Expected to Boost the glp 1 receptor agonist Market’s Growth Potential?

The GLP-1 receptor agonist market is projected to be driven by the escalating incidence of diabetes. Diabetes, a long-lasting disease, occurs when the pancreas fails to produce adequate insulin or the body is unable to effectively utilize the insulin it produces. Elevated blood sugar levels characterize the metabolic disorder known as diabetes mellitus. GLP-1 receptor agonist plays a role in diabetes management by prompting the body to generate more insulin, which contributes to reducing blood sugar levels. Consequently, an increase in diabetes cases is likely to spur market growth. As per the Office for Health Improvement and Disparities, a UK government agency, in March 2024, it was noted from March 2022 to March 2023, that there was a 22% surge in the proportion of type 1 diabetic patients who received all eight recommended care processes, and a 21% rise for type 2 diabetes patients. Also, the percentage of individuals achieving target HbA1c levels increased to a record high of 37.9%, as per the National Diabetes Audit (NDA). Hence, the increasing prevalence of diabetes is a significant factor fuelling the GLP-1 receptor agonist market.

Request Your Free GLP 1 Receptor Agonist Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

Who Are the Influential Players Reshaping the GLP 1 Receptor Agonist Market Landscape?

Major companies operating in the GLP-1 receptor agonist market include:

• Novo Nordisk A/S_x000D_

• Sanofi SA_x000D_

• Eli Lilly and Company_x000D_

• AstraZeneca Inc._x000D_

• Boehringer Ingelheim International GmbH_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the GLP 1 Receptor Agonist Market?

One prominent trend gaining traction in the GLP-1 receptor agonist market is product innovation. To fortify their market positions, leading companies in the GLP-1 receptor agonist market are focusing on producing pioneering solutions. As an example, Eli Lilly and Company, a US-based firm known for manufacturing medicines that enhance people’s lives, introduced its FDA-certified new Mounjaro, a GIP and GLP-1 receptor agonist, in May 2022. This product is uniquely developed with a single molecule that activates the body’s incretin hormones GIP and GLP-1 receptors. It is provided as an auto-injector pen with a pre-fixed, concealed needle which patients do not have to handle or see, and is available in 6 different doses.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Which Industry Segments Are Leading the Development and Expansion of the GLP 1 Receptor Agonist Market?

The GLP-1 receptor agonist market covered in this report is segmented –

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs

2) By Route Of Administration: Parenteral, Oral

3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:

1) By Exenatide: Byetta, Bydureon

2) By Liraglutide: Victoza, Saxenda

3) By Dulaglutide: Trulicity

4) By Lixisenatide: Adlyxin

5) By Other Drugs: Semaglutide, Tirzepatide, Others

Which Geographic Locations Are Critical to the Growth of the GLP 1 Receptor Agonist Market?

North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Defining Aspects of the GLP 1 Receptor Agonist Market Landscape?

A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus.

Browse Through More Similar Reports By The Business Research Company:

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

Hemodialysis And Peritoneal Dialysis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hemodialysis-and-peritoneal-dialysis-global-market-report

Blood And Blood Components Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: